Skip to main content
Premium Trial:

Request an Annual Quote

BioTrove, OSI to Offer Combination of Drug Discovery Platforms

NEW YORK (GenomeWeb News) – BioTrove said today that it has teamed up with OSI Pharmaceuticals to offer customers a combination of the firm’s drug discovery platforms.
 
The alliance will offer OSI’s Integrated Lead Discovery Platform with BioTrove’s RapidFire mass spectrometry-based assay development, screening, and analysis services. The OSI platform enables screening of large volumes of compounds against target assays, while the RapidFire platform enables label-free, high-throughput screening using biological substrates to identify active compounds within chemical libraries.
 
The companies expect that the combined tools will “enable increased research around novel targets for companies who may have crucial insights about disease progression, but do not specialize in large-scale, high-throughput screening internally,” said BioTrove President and CEO Albert Luderer in a statement.
 
Financial terms of the alliance were not disclosed.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.